Neurimmune AG, the discoverer of aducanumab and cinpanemab, announced today enrollment of the first patient in a Phase 1 clinical trial to evaluate NI006 in transthyretin amyloid cardiomyopathy (ATTR cardiomyopathy).
NI006 is a human antibody directed against transthyretin amyloid (TTR amyloid) consisting of misfolded and aggregated forms of transthyretin. Neurimmune discovered NI006 by translating genetic information of human memory B cells through its Reverse Translational Medicine technology.
The first-in-human, placebo-controlled, multicenter Phase 1 clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and exploratory efficacy of NI006 in patients with wild-type and hereditary forms of ATTR cardiomyopathy.
“This is the fifth of our recombinant human antibody programs tested in clinical trials in human diseases linked to protein aggregation and misfolding” said Roger Nitsch, Neurimmune's CEO. “Leveraging our expertise in antibodies for Alzheimer's and Parkinson's diseases enabled the discovery of evolutionarily optimized antibodies that selectively bind and remove TTR amyloid fibrils in vivo.”
NI006 is a human monocloncal antibody that binds with high affinity to TTR amyloid, but not to the physiological forms of transthyretin. In the recently initiated single and multiple ascending dose study, up to four monthly infusions of NI006 will be assessed in patients with ATTR cardiomyopathy at clinical centres in Europe.
“ATTR cardiomyopathy is characterized by the intramyocardial deposition of TTR amyloid fibrils that increase heart wall thickness and cause heart muscle stiffness leading to ventricular dysfunction”, said Christoph Hock, CMO of Neurimmune. “Our goal is to develop NI006 as a novel treatment option for patients with ATTR cardiomyopathy and to improve their heart function by clearing cardiac amyloid.”
Priority medicines (PRIME) is a scheme run by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients earlier EMA CHMP acknowledges that n
LubioScience GmbH, Switzerland’s leading Life Sciences platform, expands its product portfolio with the addition of fresh human blood products and biospecimens provided by Research Donors from the UK.
Preliminary data from 472 nine-month-old infants confirm favorable safety and tolerability profile and demonstrate significant immunogenicity for the four most common pathogen serotypes Results support further development with LimmaTech expecting to initiate the next clinical trial in 2024 Topline results from the completed Phase I/II will be reported in the first half of 2024
InterAx Biotech AG, a product development company pioneering computational pharmacology for drug discovery, announces that the company's most advanced artificial intelligence platform has uncovered novel cellular signaling modes of action which enable InterAx to design efficacious orally available drugs for diabetes, obesity, and immuno oncology. Particularly promising results are coming from the
Its proprietary innovative polymer technology reduces bacterial bioburden without triggering antimicrobial resistance, one of the top global public health threats The Advanced Wound Dressing (AWD) market is valued at 4.5 billion USD and is witnessing increasing demand and technological advancements The company is looking to expand development and commercial collaborations with industry leaders
Vandria is advancing a portfolio of mitophagy inducers to address age-related chronic diseases of the CNS, muscle, lung and liver Innosuisse grant totalling CHF 2.5M (€ 2.7M) to support early clinical development plan for lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive impairment, dementia, Alzheimer’s and Parkinson’s Disease Eurostars grant totalling €1